Earnings summaries and quarterly performance for Lipocine.
Executive leadership at Lipocine.
Board of directors at Lipocine.
Research analysts covering Lipocine.
Recent press releases and 8-K filings for LPCN.
Lipocine Announces Third Quarter 2025 Financial Results and Clinical Updates
LPCN
Earnings
New Projects/Investments
Guidance Update
- Lipocine reported a net loss of $3.2 million, or ($0.59) per diluted share, for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company had $15.1 million in unrestricted cash, cash equivalents, and marketable investment securities.
- Royalty revenue from TLANDO sales was $115,000 for the third quarter ended September 30, 2025, with no comparable revenue in the prior year period.
- The Phase 3 study for LPCN 1154 (oral brexanolone for Postpartum Depression) continues to enroll patients, with top-line data expected in the second quarter of 2026 and a 505(b)(2) New Drug Application (NDA) submission anticipated in 2026.
Nov 6, 2025, 2:40 PM
Lipocine Announces Third Quarter 2025 Financial Results and Pipeline Updates
LPCN
Earnings
New Projects/Investments
- Lipocine reported a net loss of $3.2 million, or ($0.59) per diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $2.2 million, or ($0.44) per diluted share, for the same period in 2024.
- As of September 30, 2025, the company's unrestricted cash, cash equivalents, and marketable investment securities totaled $15.1 million, a decrease from $21.6 million at December 31, 2024.
- Total revenues for the nine months ended September 30, 2025, were $831,000, a significant decrease from $7.7 million for the comparable period in 2024, primarily due to lower license revenue.
- The Phase 3 study for LPCN 1154 (oral brexanolone) for Postpartum Depression is ongoing, with top-line data expected in the second quarter of 2026 and a U.S. NDA submission anticipated in 2026. Lipocine is also exploring partnering opportunities for LPCN 1154.
Nov 6, 2025, 1:00 PM
Lipocine Presents Positive Phase 2 Clinical Data for LPCN 2401 at ObesityWeek®
LPCN
New Projects/Investments
- Lipocine presented positive 20-week Phase 2 clinical data for its drug candidate LPCN 2401 at ObesityWeek®, demonstrating rapid improvement in body composition in men with obesity.
- The trial data also indicated that LPCN 2401 improves liver health by reducing liver fat content and liver injury markers, and was well tolerated with no concerning safety signals observed through 72 weeks of exposure.
- LPCN 2401 is an oral anabolic androgen receptor agonist being developed as an adjunct therapy for obesity management, and Lipocine is actively exploring partnering opportunities for this candidate.
Nov 4, 2025, 1:00 PM
Lipocine Presents Positive LPCN 2401 Clinical Data at ObesityWeek
LPCN
New Projects/Investments
- Lipocine Inc. announced the presentation of positive clinical data for its drug candidate, LPCN 2401, at the ObesityWeek® annual meeting on November 4, 2025.
- The presented Phase 2 trial data for LPCN 2401 demonstrated rapid improvement in body composition (increased lean mass, reduced fat mass) and improved liver health in men with obesity.
- LPCN 2401 was well tolerated, with no concerning safety signals observed through 72 weeks of exposure.
- LPCN 2401 is an oral anabolic androgen receptor agonist being developed for obesity management, with Lipocine exploring partnering opportunities for the candidate.
Nov 4, 2025, 11:21 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more